Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.
The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.
Dr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it "removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care." The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。